Intellia Therapeutics NTLA Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Intellia Therapeutics's accrued liabilities, current?
- Intellia Therapeutics (NTLA) reported accrued liabilities, current of $37.92M in Q1 2026.
- How has Intellia Therapeutics's accrued liabilities, current changed year-over-year?
- Intellia Therapeutics's accrued liabilities, current decreased by 7.1% year-over-year, from $40.81M to $37.92M.
- What is the long-term trend for Intellia Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), Intellia Therapeutics's accrued liabilities, current has grown at a 14.3% compound annual growth rate (CAGR), from $25.55M to $49.86M.